First Approved CAR T-Cell Therapy Shows Continued Benefits Five Years Later
Jun 16, 2022
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
Cellular Therapy and Transplant Section News
Your child will be cared for by one of the most accomplished teams of cellular therapy and transplant experts in the world. Our team includes doctors, nurses, social workers, nutritionists, psychologists and more.
Existing patients or family members
New patients, referrals and second opinions
New Data Show Benefits of CRISPR-edited Gene Therapy for Blood Disorders in a Larger Patient Group with Longer-Term Follow-Up
Jun 14, 2022
A group of researchers that includes CHOP presented new data on CRISPR-edited gene therapy for blood disorders at an international meeting.
Penn Medicine and Children’s Hospital of Philadelphia Announce Partnership with Costa Rica for CAR T Cell Therapy
May 23, 2022
International collaboration aims to ensure more equitable access to transformative personalized cancer therapy.
CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
May 23, 2022
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
First Child to Receive Revolutionary CAR T Therapy Celebrates 10 Years Cancer Free
May 11, 2022
Emily Whitehead, now 17, received life-saving treatment at CHOP, transforming the field of cancer immunotherapy.
Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Cure 10 Years Later
May 11, 2022
Whitehead received life-saving treatment at CHOP, under the care of Dr. Stephan Grupp, transforming the field of cancer immunotherapy.
CHOP/Penn Study Shows CAR-T Cells Remain Active a Decade After Infusion
Feb 2, 2022
A new study in Nature has documented the longest persistence of CAR T cell therapy to date.
Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy
Jan 4, 2022
Aberrant splicing leads to downregulation of CD22 in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies.
Stephan Grupp, MD, PhD, a Panelist at Distinguished Conference About National Cancer Act
Dec 13, 2021
A cell and gene therapy expert, Grupp discussed progress in clinical care in the 50 years since the legislation was signed.
CHOP Gene Therapy Experts Profiled in Philadelphia Magazine
May 12, 2021
CHOP researchers were interviewed as a part of a comprehensive article about cell and gene therapy in Philadelphia Magazine.